• Kyodo

  • SHARE

Pharmaceutical giant Shionogi & Co. said Thursday it will establish a research hub in April with Chiba University Hospital to work on the development of a nasal spray vaccine to be used against COVID-19 and other respiratory infections.

Under the partnership, the company and university will work toward the swift development of a vaccine, with the aim of beginning clinical trials within fiscal 2022 starting April.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)